Lee, R. W. J., Creed, T. J., Schewitz, L. P., Newcomb, P. V., Nicholson, L. B., Dick, A. D. and Dayan, Colin Mark ORCID: https://orcid.org/0000-0002-6557-3462 2007. CD4+CD25int T cells in inflammatory diseases refractory to treatment with glucocorticoids. The Journal of Immunology 179 (11) , pp. 7941-7948. 10.4049/jimmunol.179.11.7941 |
Abstract
Up to 30% of patients with autoimmune, allergic, and lymphoproliferative diseases are refractory to glucocorticoid therapy. The present study was undertaken to investigate whether such steroid resistance (SR) is limited to a subpopulation of CD4+ T cells and, as IL-2 is a putative driver of SR, whether T cell SR is associated with CD25 expression. We show that SR patients have a characteristic subgroup of activated CD4+ T cells that continue to proliferate despite exposure to high-dose Dexamethasone (Dex), demonstrate that CD4+CD25− cells are exquisitely sensitive to Dex whereas CD4+CD25int cells are highly SR, and further find that the combination of an anti-CD25 mAb with Dex enhances suppression of T cell proliferation compared with each agent alone. We therefore conclude that SR is not a general property of all lymphocytes but resides in T cell subpopulations, which are prevalent in SR patients and express intermediary levels of CD25. As a result, we propose a new paradigm for SR disease in which glucocorticoid therapy positively selects SR cells, generating a population of drug-resistant lymphocytes that perpetuate on-going inflammation.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine Systems Immunity Research Institute (SIURI) |
Subjects: | R Medicine > R Medicine (General) |
Publisher: | American Association of Immunologists |
ISSN: | 0022-1767 |
Last Modified: | 27 Oct 2022 08:54 |
URI: | https://orca.cardiff.ac.uk/id/eprint/63710 |
Citation Data
Cited 28 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |